) is the most active, and that its activity depends upon 2 structural features: the presence of a small electron-releasing group at C-11, and further coniuLyation of the phenanthrene ring system at C-17. Of the monomethyl isomers, only the 11-methyl-17-ketone (1) 
Summary.-Direct comparison of skin-tumour induction by 15,16-dihydro-11-methylcyclopenta[a] phenanthren-17-one (1) and by benzo[a]pyrene on mouse skin, both by repeated application or by initiation with a single dose followed by promotion with croton oil, demonstrated that these two carcinogens have similar potency. After repeated application of (1) the mean latent period for skin-tumour induction was linearly related to the logarithm of the dose over a 10-fold dose range. Under these conditions, application of the aryl-hydrocarbon-hydroxylase inhibitor 7,8-benzoflavone together with (1) inhibited tumour induction by about 40%. By contrast, in the 2 -stage experiment, little effect on tumour incidence or latent period was observed when this inhibitor was applied with the single initiating dose of (1). Co-administration of the epoxide -hydratase inhibitor 1, 1, 1 -trichloropropene oxide caused enhancement by shortening the latent period.
After s.c. injection of (1) into mice, a similar number of tumours was induced on skin remote from the site of injection by promotion with croton oil begun either one week or 6 months after initiation. Gastric instillation of (1) (Coombs & Croft, 1969) . Comparisons of the carcinogenicity of some 40 closely related members of this series have revealed that the title compound (1) (see Fig. 1 ) is the most active, and that its activity depends upon 2 structural features: the presence of a small electron-releasing group at C-11, and further coniuLyation of the phenanthrene ring system at C-17. Of the monomethyl isomers, only the 11-methyl-17-ketone (1) is strongly carcinogenic; the 7-methyl-17-ketone is a weak carcinogen whilst the 2-. 3-. 4-. 6-, and 12-methyl isomers are inactive, as is the unsubstituted parent ketone (V) (Coombs & Croft, 1969 
MATERIALS AND METHODS
Che,tiiica18. The cvclopenta [a] pheiiaiithrenes (1), JV) and (V) Nvere synthesized here, as already described (Coombs, 1966; . Usually lcm tumours, were carcinomas when induced by repeated application of the carcinouen (Table 1) , but papillomas were more common -,ihen produced by initiation and promotion (Tables  11 and 111 (Fisher, 1954 (Jerina et al., 1978) is metabolically activated by conversion to its bay-region, 3,4-dihydro-3 . 4 dihydroxy 1, 2 dihydro 1, 2 epoxide (Coombs et al., 1979) . It therefore seems probable that (1) represents the smallest conjugated system that can be activated by this mechanism to display strong carcinogenic activity. No evidence for carcinogenicity was found for its 1,2,3,4-tetrahydro derivative (IV), in keeping with the proposed activation mechanism, for this compound lacks the necessary double bonds for metabolic formation of a bay-region diol-epoxide.
At the lowest dose (5 /ig twice weekly) co-administration of the aryl-hydrocarbon- tected during the 18th week after intragastric treatment of rats with 30 mg of the carcinogen (1), but the single spontaneous tumour did not appear in the untreated group until the 42nd week. Differences in tumour incidence between the two groups was significant at 20 weeks and highly significant at 50 weeks (Table V) . By (Fisher, 1954) .
hydroxylase inhibitor, 7,8-benzoflavone (15 /-tg) reduced the carcinogenicity of (1), in agreement with previous observations (Coombs et al., 1975 (Selkirk et al., 1974) but the ultimate carcinogen, the 7,8-dihydroxy-9,10-epoxide, is apparently not a substrate for this enzyme (Wood et al., 1976 In the experiments so far described involving topical application of (1), tumour formation is confined to the treated skin.
The injection (mouse) and feeding (rat) experiments demonstrate that this carcinoo,en is also active systemically, and in more than one animal species. Previously, injection of (1) (8 and 50 mg) into mice led to ventral skin tumours as well as sarcomas at the site of injection (Coombs & Croft, 1969 (Coombs & Croft, 1969) or in the two-stage system with an "initiating" dose of 400 tkg (Coombs & Bhatt, 1, 978) .
In its ability to induce mammary carcinomas after a single intragastric instillation of 30 mg, compound (1) resembles other known potent carcinogens such as 3-methylcholant,hrene (Shay et al., 1949.) and 7) 12 dimethylbenz ra] anthracene (Huggins, 1961) . However, it is less potent than either of these, both in this regard and also as jtidged by their relative mean latent periods for induction of skin tumours in mice (Coombs & Croft, 1.969 
